CClinicalTrials.gg
CompletedNCT05447507Updated Nov 29, 2022

Comparison of Remimazolam and Dexmedetomidine for Intraoperative Sedation

A Phase 4 interventional study of Remimazolam and Dexmedetomidine in Orthopedic Disorder, sponsored by Seoul National University Hospital. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-11-29.

Sponsored by Seoul National University Hospital · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
104
Allocation
Randomized
Ages
19 Years to 70 Years
Sex
All
01

Study summary

The purpose of this study is to compare the sedation efficacy of dexmedetomidine and remimazolam for intraoperative sedation during regional block.

02

Conditions studied

  • Orthopedic Disorder
03

In context

Musculoskeletal Diseases

657 studies on the registry are indexed under Musculoskeletal Diseases; 159 are open to participants now.

This study's enrollment of 104 is above the median of 73 across 438 interventional studies indexed under Musculoskeletal Diseases.

Browse Musculoskeletal Diseases studies →

Lead sponsor

Seoul National University Hospital is the lead sponsor of 1,860 studies on the registry; 275 are open to participants now.

Of its 12 completed or terminated interventional studies of FDA-regulated products, 2 (17%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patient scheduled for lower extremity surgery under regional anesthesia, aged 19-70, of ASA class I or II.

Exclusion criteria

Exclusion Criteria:

  • Patient refusal
  • Contraindications to regional or neuraxial anesthesia (patient refusal, increased intracranial pressure, infection at puncture site, underlying neurologic disease, severe hypovolemia, aortic or mitral stenosis, thrombocytopenia or coagulopathy)
  • Contraindications to dexmedetomidine or remimazolam administration
  • Allergy to dexmedetomidine or remimazolam
  • Baseline MOAA/S score of 4 or less
  • Pregnancy
  • Other conditions considered unsuitable by the investigators
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
104 participants (actual)

Study arms

  • Active comparator
    Remimazolam

    Drug: Remimazolam

  • Active comparator
    Dexmedetomidine

    Drug: Dexmedetomidine

Interventions

  • DrugRemimazolam

    0.075 mg/kg Remimazolam bolus infusion for 1 min, then 0.5\~1.0 mg/kg/h continuous infusion

  • DrugDexmedetomidine

    1 mcg/kg Dexmedetomidine infusion for 10 min, then 0.2\~0.7 mcg/kg/h continuous infusion

06

What researchers measure

Primary outcomes

  1. Number of rescue sedative doses administered

    Time frame: Intraoperative period

Secondary outcomes

  1. Incidence of intraoperative bradycardia (heart rate lower than 45 bpm)

    Time frame: Intraoperative period

  2. Incidence of intraoperative hypotension (mean blood pressure lower than 65 mmHg or systolic blood pressure lower than 80% of baseline)

    Time frame: Intraoperative period

  3. Incidence of intraoperative hypertension (systolic blood pressure higher than 120% of baseline)

    Time frame: Intraoperative period

  4. Incidence of respiratory depression (respiratory rate lower than 8 per minute)

    Time frame: Intraoperative period

  5. Incidence of hypoxia (oxygen saturation detected by pulse oxymetry less than 93%)

    Time frame: Intraoperative period

  6. MOAA/S score (Modified Observer's Assessment of Alertness and Sedation, 0=unarousable, 5=alert)

    Time frame: Intraoperative period

  7. Intraoperative PSi (Patient State index)

    Time frame: Intraoperative period

  8. Electroencephalogram data (alpha, beta, delta, theta waves)

    Time frame: Intraoperative period

  9. Time to reach MOAA/S = 5 after end of drug infusion

    Time frame: Intraoperative period and post-anesthesia care period (immediate post-operative period)

  10. Oxygen supply at the post-anesthesia care unit

    Time frame: Post-anesthesia care period (immediate post-operative period)

  11. Incidence of postoperative delirium

    Time frame: Immediately after the surgery, up to 5 days after surgery

  12. Incidence of nausea/vomiting

    Time frame: Intraoperative period and post-anesthesia care period (immediate post-operative period)

  13. Postoperative spinal anesthesia block level

    Time frame: Postoperative period, up to 12h hours after end of surgery

  14. Duration of stay in the post-anesthsia care unit(PACU)

    Time frame: Immediate postoperative period

  15. Patient satisfaction (numerical rating scale of 0~10)

    0 Not at all satisfied, 10 very satisfied

    Time frame: Immediately after the surgery, up to 5 days after surgery

  16. Serum CRP level

    Time frame: Preoperative baseline and second postoperative day

07

Study locations

1 site
  • Seoul National University Hospital
    Seoul, Jongno-gu 03080, Korea, Republic of
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 29, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05447507
Lead sponsor
Seoul National University Hospital
Responsible party
Jin-Tae Kim (Professor, Seoul National University Hospital) — Principal investigator
First posted
Jul 7, 2022
Start date
Jul 8, 2022
Primary completion
Oct 26, 2022
Completion
Oct 26, 2022
Last update
Nov 29, 2022

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion